Connection | Profiles RNS

Search Result Details

Back to Search Results

This page shows the details of why an item matched the keywords from your search.

Search Results

Garassino, Marina Chiara

One or more keywords matched the following items that are connected to Garassino, Marina Chiara

Item Type	Name
Concept	Adjuvants, Immunologic
Concept	Immunosuppressive Agents
Concept	Immunoglobulin Fc Fragments
Concept	Immunologic Factors
Concept	Dose-Response Relationship, Drug
Concept	Immunotherapy
Concept	Immunohistochemistry
Concept	Immunoglobulin G
Concept	Angiogenesis Inhibitors
Concept	NF-E2-Related Factor 2
Concept	Histone Deacetylase Inhibitors
Concept	Cell Cycle Checkpoints
Concept	Immunity
Concept	Protein Kinase Inhibitors
Concept	Proton Pump Inhibitors
Academic Article	Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Academic Article	Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
Academic Article	Severity of COVID-19 in patients with lung cancer: evidence and challenges.
Academic Article	DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation.
Academic Article	The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST.
Academic Article	Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Academic Article	Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
Academic Article	Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis.
Academic Article	Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system.
Academic Article	Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).
Academic Article	Regulation of PD-L1 Expression by NF-?B in Cancer.
Academic Article	Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer.
Academic Article	Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy.
Academic Article	Choosing the Best Chemotherapy Agent to Boost Immune Checkpoint Inhibition Activity.
Academic Article	Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations.
Academic Article	Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer.
Academic Article	Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.
Academic Article	Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Academic Article	Immunometabolic Status of COVID-19 Cancer Patients.
Academic Article	Association of Steroids use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Academic Article	Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy.
Academic Article	Correction to Lancet Oncol 2015; 16: 747. EGFR mutations and EGFR tyrosine kinase inhibitors.
Academic Article	Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer.
Academic Article	Clinical and molecular determinants of survival in pancreatic cancer patients treated with second-line chemotherapy: results of an Italian/Swiss multicenter survey.
Academic Article	Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.
Academic Article	At the Crossroads: COVID-19 and Immune-Checkpoint Blockade for Cancer.
Academic Article	Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.
Academic Article	Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer.
Academic Article	Chemotherapy versus tyrosine kinase inhibitor in EGFR unselected population advanced non-small cell lung cancer still matter of debate?-An update incorporating the DELTA trial data.
Academic Article	Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy.
Academic Article	Is impaired response to PD-1 blockers of high serum PD-1 patients related to immune complexes?
Academic Article	Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis.
Academic Article	EGFR mutations and EGFR tyrosine kinase inhibitors.
Academic Article	Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?
Academic Article	Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer.
Academic Article	Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases.
Academic Article	Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade.
Academic Article	Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Academic Article	Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung Cancer.
Academic Article	Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey.
Academic Article	Development and clinical indications of cetuximab.
Academic Article	Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors: from guidelines to clinical practice in solid tumors.
Academic Article	Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer.
Academic Article	Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study.
Academic Article	Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers.
Academic Article	ALK/ROS1 rearrangements: A real hallmark for thromboembolic events in cancer patients?
Academic Article	Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis.
Academic Article	BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience.
Academic Article	Shifting From a "One Size Fits All" to a Tailored Approach for Immune-Related Adverse Events.
Academic Article	Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.
Academic Article	Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy.
Academic Article	Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients.
Academic Article	Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study.
Academic Article	Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don't) know.
Academic Article	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future.
Academic Article	To target or not to target, that is the question.
Academic Article	Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms.
Academic Article	Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells.
Academic Article	Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out.
Academic Article	Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.
Academic Article	First Case Report of Pregnancy on Alectinib in a Woman With Metastatic ALK-Rearranged Lung Cancer: A Case Report.
Academic Article	Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression.
Academic Article	Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program.
Academic Article	Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer.
Academic Article	Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study.
Academic Article	Do we really need another epidermal growth factor receptor tyrosine kinase inhibitor in first-line treatment for patients with non-small-cell lung cancer and EGFR mutations?
Academic Article	Doing more with less: fluorescence in situ hybridization and gene sequencing assays can be reliably performed on archival stained tumor tissue sections.
Academic Article	Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients.
Academic Article	Unusual skin toxicity associated with sustained disease response induced by nivolumab in a patient with non-small cell lung cancer.
Academic Article	Testing epidermal growth factor receptor mutations in patients with non-small-cell lung cancer to choose chemotherapy: the other side of the coin.
Academic Article	Relationship Between Programmed Death Receptor-Ligand 1 Expression and Response to Checkpoint Inhibitor Immunotherapy in Pulmonary Sarcomatoid Carcinoma: A Pooled Analysis.
Academic Article	Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting.
Academic Article	Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis.
Academic Article	Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review.
Academic Article	Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 =50% who progress on first-line immunotherapy: real-world data from a European cohort.
Academic Article	Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score =50% treated with front-line pembrolizumab.
Academic Article	Myeloid cell heterogeneity in lung cancer: implication for immunotherapy.
Academic Article	CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).
Academic Article	Targeting the MET gene for the treatment of non-small-cell lung cancer.
Academic Article	Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders.
Academic Article	Afatinib for lung cancer: let there be light?
Academic Article	Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to Emerge.
Academic Article	Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib.
Academic Article	Challenging Lung Carcinoma with Coexistent ?Np63/p40 and Thyroid Transcription Factor-1 Labeling Within the Same Individual Tumor Cells.
Academic Article	Is the chemotherapy era in advanced non-small cell lung cancer really over? Maybe not yet.
Academic Article	LKB1 Deficiency Renders NSCLC Cells Sensitive to ERK Inhibitors.
Academic Article	Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number.
Academic Article	EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort.
Academic Article	Immunotherapy: a new standard of care in thoracic malignancies? A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly.
Academic Article	Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors.
Academic Article	Does immunohistochemistry affect response to therapy and survival of inoperable non-small cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases.
Academic Article	Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer.
Academic Article	Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.
Academic Article	Evaluation of Drug-Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors.
Academic Article	Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer.
Academic Article	Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations.
Academic Article	Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology.
Academic Article	Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series.
Academic Article	Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial.
Academic Article	Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer.
Academic Article	Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy.
Academic Article	Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy.
Academic Article	Adenosine Pathway in NSCLC With Molecular Drivers: Can Oncogene Addiction Translate Into Immune Addiction?
Academic Article	Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis.
Academic Article	Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial.
Academic Article	Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies.
Academic Article	Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy.
Academic Article	Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors.
Academic Article	Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC.
Academic Article	PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers.
Academic Article	Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis.
Academic Article	Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer.
Academic Article	Is hyperprogressive disease a specific phenomenom of immunotherapy?
Academic Article	Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study.
Academic Article	Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients.
Concept	Immunosenescence
Concept	Antineoplastic Agents, Immunological
Concept	Proteasome Inhibitors
Academic Article	Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4).
Academic Article	The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy.
Academic Article	Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
Academic Article	Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer.
Academic Article	PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis.
Academic Article	What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer?
Academic Article	Real-World Treatment Patterns and Outcomes of First-Line Immunotherapy Among Patients With Advanced Nonsquamous NSCLC Harboring BRAF, MET, or HER2 Alterations.
Academic Article	Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver Alterations.
Academic Article	High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors.
Academic Article	Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies.
Academic Article	Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT).
Academic Article	Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy.
Academic Article	Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC.

Search Criteria

immune
related
Adverse
Events
checkpoint
inhibitor
immunotherapy